troglitazone has been researched along with Chronic Illness in 6 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 7.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 7.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 7.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 3.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| " In this study, we investigated the effect of a TZD, troglitazone, on inflammation and fibrogenesis in the pancreas of an experimental model of chronic pancreatitis." | 3.73 | Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation. ( Hisada, S; Kobayashi, M; Shimizu, K; Shiratori, K, 2005) |
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 3.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 3.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| "2% troglitazone was administered from 1 month to 7 months of age in WBN/Kob rats with spontaneous chronic pancreatitis." | 3.71 | Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. ( Fujiwara, T; Hayashi, N; Horikoshi, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2002) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graham, DJ | 1 |
| Green, L | 1 |
| Senior, JR | 1 |
| Nourjah, P | 1 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 1 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Shimizu, K | 3 |
| Shiratori, K | 3 |
| Kobayashi, M | 3 |
| Kawamata, H | 1 |
| van Westerloo, DJ | 1 |
| Florquin, S | 1 |
| de Boer, AM | 1 |
| Daalhuisen, J | 1 |
| de Vos, AF | 1 |
| Bruno, MJ | 1 |
| van der Poll, T | 1 |
| Hisada, S | 1 |
| Hayashi, N | 1 |
| Fujiwara, T | 1 |
| Horikoshi, H | 1 |
1 trial available for troglitazone and Chronic Illness
| Article | Year |
|---|---|
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
5 other studies available for troglitazone and Chronic Illness
| Article | Year |
|---|---|
Troglitazone-induced liver failure: a case study.
Topics: Age Distribution; Aged; Chemical and Drug Induced Liver Injury; Chromans; Chronic Disease; Confidenc | 2003 |
Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism.
Topics: Actins; Animals; Cell Division; Cells, Cultured; Chromans; Chronic Disease; Disease Progression; Dru | 2004 |
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Topics: Actins; Animals; Cell Differentiation; Ceruletide; Chromans; Chronic Disease; Collagen; Disease Mode | 2005 |
Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation.
Topics: Actins; Animals; Antineoplastic Agents; Chromans; Chronic Disease; Collagen Type I; Collagen Type II | 2005 |
Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis.
Topics: Amylases; Animals; Antineoplastic Agents; Blood Glucose; Chromans; Chronic Disease; Disease Models, | 2002 |